Friday, September 20, 2013

GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy $rna $gsk $srpt down 75% !

GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy $rna $gsk $srpt

No comments:

Post a Comment